This Viewpoint considers the lawsuit United States v Gilead Sciences in the context of intellectual property rights and the patents held on medications for preexposure prophylaxis (PrEP) for HIV infection, leading to a trade-off between affordability and future pharmaceutical collaboration and innovation.